Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

NTX-001

Phase 2Small molecule

MMajor Extremity Trauma Research Consortium

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral Nerve InjuriesActive, not recruiting

Peripheral Nerve InjuriesPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Peripheral Nerve Injuries

NCT04789044

Clinical

Trials by Indication[1]

Peripheral Nerve Injuries1 trial

A Phase 2a Multicenter Randomized Controlled Trial Evaluating the Safety and Efficacy of Polyethylene Glycol (PEG) Mediated Fusion (PEG Fusion) Compared to Standard of Care in the Repair of Mixed Motor-sensory Acute Peripheral Nerve Injuries (PNI) for Rapid and Immediate Improvement in Outcome

Active, not recruiting·MMajor Extremity Trauma Research Consortium·Phase 2·NCT04789044·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NTX-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NTX-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NTX-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Major Extremity Trauma Research Consortium company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMajor Extremity Trauma Research Consortium

Related News